Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 4 min ago
Peer-reviewedCC BY 4.0JCI Insight

Menin inhibition impairs metastatic colonization of Ewing sarcoma

  • Katherine A. Braun1
  • Nicolas M. Garcia1
  • Mohamed A. Ahmed1
  • Darleen S. Tu1
  • Stephanie I. Walter1
  • Emma D. Wrenn1
  • Megan E.B. Dean1
  • Neerja Katiyar1,2
  • Elizabeth R. Lawlor1,3,4
4 affiliations
  1. 1Ben Towne Center for Childhood Cancer and Blood Disorders Research and
  2. 2Research Scientific Computing, Seattle Children’s Research Institute, Seattle, Washington, USA.
  3. 3Division of Pediatric Hematology, Oncology, Bone Marrow Transplantation, and Cellular Therapies, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.
  4. 4Division of Human Biology, Fred Hutch Cancer Center, Seattle, Washington, USA.
Read full textPDFDOICite

Abstract

Menin is a scaffolding protein that interacts with context-specific partners to regulate gene expression. In rearranged mixed-lineage leukemia, Menin-MLL interactions drive leukemogenesis and Menin inhibitors have been FDA approved for these cancers. We previously reported that Menin promotes oncogenic phenotypes in Ewing sarcoma (EwS). Here, we sought to define EwS-specific functions of Menin and determine if Menin inhibitors could be therapeutically leveraged for these tumors. Genetic KO of Menin had no effect on EwS cell proliferation in vitro, but metastatic potential of Menin-depleted cells in vivo was impaired. Transcriptional profiling of Menin-KO cells in vitro showed reproducible downregulation of MYC signature genes and upregulation of developmental programs. Conversely, transcriptional rewiring of developmental genes and restoration of MYC target gene expression were evident in tumors that arose from Menin-KO cells. Exposing EwS cells to the Menin inhibitor VTP50469 (revumenib) inhibited expression of MYC targets, and coimmunoprecipitation studies detected Menin-MYC interactions that were partially disrupted by the drug. Metastatic colonization of disseminated EwS cells in vivo was significantly inhibited in mice fed VTP50469 chow. Together these findings implicate Menin as a mediator of EwS metastasis and suggest that Menin inhibitors warrant investigation as novel therapeutics for patients with high-risk disease.

Related

  1. Primary renal Ewing sarcoma with extensive metastatic disease at diagnosis: A case report and literature review
    Juan Ignacio Caicedo, María Alejandra Cote Martínez, David Santiago Torres-Leal +3
    Urology case reportsPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma
    James H. McGinnis, Shuai Wang, Ryan A. O’Hara +22
    Cancer discoveryPeer-reviewedLicence not statedFull text1 citedGeneral medicinePMC
  3. Enhanced Recovery After Surgery (ERAS) Protocols in Sarcoma and Metastatic Bone Disease: A Scoping Review
    Leah Ferrie, Alex Gamage, Peter Lewkonia +6
    CancersPeer-reviewedCC BY 4.0Surgery & anaesthesiaCrossref
  4. Revisiting AXL as a therapeutic target in soft tissue sarcoma: dubermatinib and bemcentinib effects are largely independent of AXL inhibition
    C. Garnes-Garcia, P. Fernandez-Aroca, F. J. Cimas +7
    bioRxivPreprintCC BY-NCFull textOncologybioRxiv
  5. 1105 HER3 inhibition sensitizes metastatic colorectal and pancreatic cancer to immunotherapy
    Rui Wang, Elizabeth Bryson, Chao Wei +3
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ

Cite

BibTeXRIS
BibTeX
@article{braun2026menin,
  title = {{Menin inhibition impairs metastatic colonization of Ewing sarcoma}},
  author = {Katherine A. Braun and Nicolas M. Garcia and Mohamed A. Ahmed and Darleen S. Tu and Stephanie I. Walter and Emma D. Wrenn and Megan E.B. Dean and Neerja Katiyar and Elizabeth R. Lawlor},
  journal = {JCI Insight},
  year = {2026},
  month = sep,
  doi = {10.1172/jci.insight.202419},
  url = {https://doi.org/10.1172/jci.insight.202419},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Menin inhibition impairs metastatic colonization of Ewing sarcoma
AU  - Katherine A. Braun
AU  - Nicolas M. Garcia
AU  - Mohamed A. Ahmed
AU  - Darleen S. Tu
AU  - Stephanie I. Walter
AU  - Emma D. Wrenn
AU  - Megan E.B. Dean
AU  - Neerja Katiyar
AU  - Elizabeth R. Lawlor
PY  - 2026
DA  - 2026/09/01
JO  - JCI Insight
DO  - 10.1172/jci.insight.202419
UR  - https://doi.org/10.1172/jci.insight.202419
AB  - Menin is a scaffolding protein that interacts with context-specific partners to regulate gene expression. In rearranged mixed-lineage leukemia, Menin-MLL interactions drive leukemogenesis and Menin inhibitors have been FDA approved for these cancers. We previously reported that Menin promotes oncogenic phenotypes in Ewing sarcoma (EwS). Here, we sought to define EwS-specific functions of Menin and determine if Menin inhibitors could be therapeutically leveraged for these tumors. Genetic KO of Menin had no effect on EwS cell proliferation in vitro, but metastatic potential of Menin-depleted cells in vivo was impaired. Transcriptional profiling of Menin-KO cells in vitro showed reproducible downregulation of MYC signature genes and upregulation of developmental programs. Conversely, transcriptional rewiring of developmental genes and restoration of MYC target gene expression were evident in tumors that arose from Menin-KO cells. Exposing EwS cells to the Menin inhibitor VTP50469 (revumenib) inhibited expression of MYC targets, and coimmunoprecipitation studies detected Menin-MYC interactions that were partially disrupted by the drug. Metastatic colonization of disseminated EwS cells in vivo was significantly inhibited in mice fed VTP50469 chow. Together these findings implicate Menin as a mediator of EwS metastasis and suggest that Menin inhibitors warrant investigation as novel therapeutics for patients with high-risk disease.
SN  - 2379-3708
ER  -